Coya Therapeutics has enrolled the 100th patient in its Phase 2/3 ALSTARS trial of COYA 302 for ALS. The study is expected to reach its 120-participant target in time for topline data in early Q2 2027, giving investors a defined clinical-development milestone to monitor.
Key Highlights
- ALSTARS will randomize approximately 120 ALS patients equally among two COYA 302 dosing regimens and placebo.
- The initial double-blind treatment period lasts 24 weeks, followed by a 24-week blinded active-treatment extension for eligible patients.
- The trial’s primary endpoint measures change in ALSFRS-R total score through Week 24 against placebo.
Coya Therapeutics, Inc. (NASDAQ: COYA) has enrolled the 100th patient in its ongoing Phase 2/3 ALSTARS trial evaluating COYA 302 in amyotrophic lateral sclerosis. Based on current enrollment trends, Coya expects to complete enrollment of 120 participants in time to report topline data in early Q2 of 2027.
COYA 302 combines proprietary low-dose IL-2 with CTLA-4 Ig. Approximately 120 participants will be assigned equally among two pre-specified COYA 302 dosing regimens and placebo. The initial double-blind treatment period lasts 24 weeks, followed by a 24-week blinded active-treatment extension for patients who complete that phase. The trial also evaluates efficacy, safety, tolerability, biological activity and biomarker levels. Patients assigned to COYA 302 remain on their designated regimen during the extension phase.
FAQs
Q: What is the Coya Therapeutics ALSTARS trial testing?
A: The Phase 2/3 ALSTARS trial is evaluating COYA 302 in amyotrophic lateral sclerosis. COYA 302 combines proprietary low-dose IL-2 with CTLA-4 Ig.
Q: When does Coya Therapeutics expect ALSTARS topline data?
A: Coya Therapeutics anticipates reporting topline ALSTARS data in early Q2 of 2027. The expectation is based on current enrollment trends and follows completion of the planned participant enrollment.
Q: What is the primary endpoint of the ALSTARS trial?
A: The primary endpoint measures change in the ALSFRS-R total score from baseline to Week 24. The result will be compared with placebo to assess disease severity over time.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.